Vaccine development; viral vectors; gene transfer; HIV and SIV
Key words: SIV; HIV; AAV; Vaccine; Gene Transfer
Description of Research
Our laboratory has two main programs: (i) vaccine development (especially for HIV) and (ii) development of recombinant adeno-associated virus (rAAV) as a vector for human gene transfer. We have 25 years of experience in developing viral vectors for the delivery of vaccine antigens and the use of animal models to evaluate vaccine strategies. Our main interest continues to be prophylactic vaccines for HIV. Candidate vaccines developed in our laboratory have reached phase II human testing. More recently, we have begun the explore the use of rAAV vectors to deliver genes that encode antibodies which neutralize HIV (Nat Med. 2009; 15:901-6) A human phase I trial of this strategy is being planned. The laboratory also continues to seek novel uses for rAAV vectors in the treatment of human and animal diseases.
A variety of projects are available.
Jeff Connell - Quality & Safety Manager, Mary Connell - Research Lab Director, Erica Koff - Research Technician I, Bruce Schnepp - Scientist, Teihui Liu - Research Associate II.
- Professor of Pediatrics at University of Pennsylvania School of Medicine (2005– present)
- M.D., Medicine, University of North Carolina - Chapel Hill (1980)
- B.A., Chemistry and Interdisciplinary Studies, University of North Carolina - Chapel Hill (1976)
- Oscherwitz J, Yu F, Jacobs JL,Liu T-H, Johnson PR, Cease IB. A synthetic peptide vaccine targeting a cryptic neutralizing epitope in domain 2 of Bacillus anthracis protective antigen.. Infection and Immunity (published online ahead of print). 2009 June.
- Schnepp Bruce C, Jensen Ryan L, Clark K Reed, Johnson Philip R. Infectious molecular clones of adeno-associated virus isolated directly from human tissues.. Journal of virology. Vol 83(3) . 2009 Feb:1456-64.
- Liu Te-Hui, Oscherwitz Jon, Schnepp Bruce, Jacobs Jana, Yu Fen, Cease Kemp B, Johnson Philip R. Genetic vaccines for anthrax based on recombinant adeno-associated virus vectors.. Molecular Therapy. Vol 17(2) . 2009 Feb:373-9.
- Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, Desrosiers RC, and Clark KR.. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nature Medicine. Vol in press. 2009.
- Clément N, Battaglioli G, Jensen RL, Schnepp BC, Johnson PR, St. George K, and Linden RM.. Prevalence of Human Bocavirus in Human Tonsils and Adenoids. Emer Infect Dis. Vol in press. 2009.
- Mehendale S, van Lunzen J, Clumeck N, Rockstroh J, Vets E, Johnson PR, Anklesaria P, Barin B, Boaz M, Kochhar S, Lehrman J, Schmidt C, Peeters M, Schwarze-Zander C, Kabamba K, Glaunsinger T, Sahay S, Thakar M, Paranjape M, Gilmour J, Excler J-L, Fast P, and Heald AE.. A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV-1 Subtype C Adeno-Associated Virus Vaccine. AIDS Res Hum Retroviruses. Vol 24. 2008:873-80.
- Harrington Patrick R, Connell Mary J, Meeker Rick B, Johnson Philip R, Swanstrom Ronald. Dynamics of simian immunodeficiency virus populations in blood and cerebrospinal fluid over the full course of infection.. The Journal of infectious diseases. Vol 196(7) . 2007 Oct:1058-67.
- Schnepp Bruce C, Jensen Ryan L, Chen Chun-Liang, Johnson Philip R, Clark K Reed. Characterization of adeno-associated virus genomes isolated from human tissues.. Journal of virology. Vol 79(23) . 2005 Dec:14793-803.
- Chen Chun-Liang, Jensen Ryan L, Schnepp Bruce C, Connell Mary J, Shell Richard, Sferra Thomas J, Bartlett Jeffrey S, Clark K Reed, Johnson Philip R. Molecular characterization of adeno-associated viruses infecting children.. Journal of virology. Vol 79(23) . 2005 Dec:14781-92.
- Johnston Robert E, Johnson Philip R, Connell Mary J, Montefiori David C, West Ande, Collier Martha L, Cecil Chad, Swanstrom Ronald, Frelinger Jeffrey A, Davis Nancy L. Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660.. Vaccine. Vol 23(42) . 2005 Oct:4969-79.